Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Paresh Pai"'
Autor:
Paresh Pai, Varinder S Bedi, Dhanesh R Kamerkar, Robbie George, Kumud M Rai, P C Gupta, Raghuram Sekhar, Venugopal Balaji, Rajiv Parakh, S R Subramanian, Vijay Thakore, Tapish Sahu, Ravul Jindal
Publikováno v:
Indian Journal of Vascular and Endovascular Surgery, Vol 11, Iss 1, Pp 4-14 (2024)
Currently, there are no guidelines or consensus recommendations on the antithrombotic management of peripheral artery disease (PAD) from an Indian perspective. In this article, we have summarized clinical practice recommendations on antithrombotic ma
Externí odkaz:
https://doaj.org/article/faeb3a251c69465f9aee7d95d2e67d3c
Autor:
Lai Heng Lee, Pongwut Danchaivijitr, Noppacharn Uaprasert, Harinder Gill, Dennis Lee Sacdalan, Gwo Fuang Ho, Rajiv Parakh, Paresh Pai, Jen-Kuang Lee, Nannette Rey, Alexander T. Cohen
Publikováno v:
Experimental Hematology & Oncology, Vol 11, Iss 1, Pp 1-12 (2022)
Abstract Cancer-associated thrombosis (CAT) poses a significant disease burden and the incidence in Asian populations is increasing. Anticoagulation is the cornerstone of treatment, but can be challenging due to the high bleeding risk in some cancers
Externí odkaz:
https://doaj.org/article/f8e8245f9f74492e9c9da1eac8ac3864
Autor:
Balbir, Singh, Paresh, Pai, Harish, Kumar, Sheeba, George, Sandeep, Mahapatra, Vineet, Garg, G N, Gupta, Kiran, Makineni, Gaurav, Ganeshwala, Pravin, Narkhede, Syed M H, Naqvi, Kumar, Gaurav, Mohammed Y K, Hukkeri
Publikováno v:
Cardiology and Therapy. 11:49-79
Non-vitamin K antagonist oral anticoagulants (NOACs) are a new class of anticoagulant drugs used in the prevention and treatment of venous thromboembolism (VTE) and atrial fibrillation (AF). Anticoagulation requires the integration of the correct typ
Autor:
Sucheta Pandit, Mohammed Yunus Khan, Paresh Pai, Pragati Gupta, Kumud Rai, M Rajkumar, Madhur Jain, Kumar Gaurav, Amey Mane, Anand Subramaniyan, Tapish Sahu, Pinjala Ramakrishna
Publikováno v:
Drugs - Real World Outcomes. 9:109-119
Fondaparinux is the first approved anticoagulant drug among factor Xa inhibitors, with proven effectiveness and safety in preventing deep vein thrombosis. However, limited data are available supporting the benefit-risk profile of fondaparinux vs enox